These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10763451)

  • 1. Zatosetron. (LY 191617, LY 277359).
    Drugs R D; 1999 Dec; 2(6):397-9. PubMed ID: 10763451
    [No Abstract]   [Full Text] [Related]  

  • 2. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 3. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itasetron. DAU 6215, U 98079.
    Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.
    Smith WT; Londborg PD; Blomgren SL; Tollefson GD; Sayler ME
    J Clin Psychopharmacol; 1999 Apr; 19(2):125-31. PubMed ID: 10211913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
    Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ
    J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
    Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A
    Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current views on migraine and anti-migraine preparations].
    Ignatov IuD; Skoromets AA; Amelin AV
    Vestn Ross Akad Med Nauk; 2003; (10):13-9. PubMed ID: 14598505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
    Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E
    Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the new antimigraine drug serotonin receptor antagonist tropoxin on platelet aggregation].
    Vasil'eva TM; Petrukhina GN; Miftakhova NT; Makarov VA; Gan'shina TS; Bezhanian SG; Mirzoian RS
    Eksp Klin Farmakol; 2005; 68(3):30-3. PubMed ID: 16047677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.
    Ring BJ; Parli CJ; George MC; Wrighton SA
    Drug Metab Dispos; 1994; 22(3):352-7. PubMed ID: 8070310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of free concentration of SDZ ICM 567 in blood and muscle using microdialysis sampling.
    van Amsterdam C; Boukhabza A; Ofner B; Pacha W; Lemaire M
    Biopharm Drug Dispos; 1995 Aug; 16(6):521-7. PubMed ID: 7579033
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tropoxin--a new serotonin antagonist and potential antimigraine agent].
    Mirzoian RS; Seredenin SB; Gan'shina TS; Kostochka LM; Romanycheva NA; Rusakov DIu
    Eksp Klin Farmakol; 1998; 61(3):28-31. PubMed ID: 9690072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax Yields Strong Responses in CLL.
    Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eziopitant. Pfizer.
    Evangelista S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1441-3. PubMed ID: 11890362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of sumatriptan in the treatment of migraine.
    Gross M
    Br J Clin Pract; 1993; 47(4):205-7. PubMed ID: 8260340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new approach in the treatment of vascular headaches].
    D'Attoma G; Nacci MG; D'Attoma A; Piccione M
    Minerva Med; 1985 May; 76(21):1019-21. PubMed ID: 2860620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tedisamil. KC 8857.
    Drugs R D; 1999 Apr; 1(4):327-30. PubMed ID: 10566055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.